AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales
Links shared publicly online about this topic.
- 1,641total visits
AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales
AstraZeneca, Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million.
View full resource at news-medical.net
Tags: Vaccination, Flu, H1N1, Beta Blocker, Vaccine, Toprol-XL, AstraZeneca
Most Recently Shared on October 29, 2009 at 6:15 pm By:
H1N1 Swine Flu News: AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales: As.. http://twurl.nl/aumdtg
Advertisement
